Why the study?
Does concomitant treatment with candesartan and metoprolol prevent early decline in global left ventricular function in patients treated for early breast cancer with adjuvant anthracycline-containing regimens?
Does concomitant treatment with candesartan and metoprolol prevent early decline in global left ventricular function in patients treated for early breast cancer with adjuvant anthracycline-containing regimens?
Concomitant treatment with candesartan protects against early decline in left ventricular function in patients receiving anthracycline-containing regimens for early breast cancer.
Supports candesartan co-use to mitigate early LV decline during anthracycline therapy in breast cancer; extends RCT evidence for cardioprotection in this setting.
In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricular function.
No takes yet. Share an insight, caveat, or question.
Gulati et al. (2016) studied this question.